CytomX Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
The information set forth below is included for the purpose of providing disclosure under “Item 1.02 – Termination of a Material Definitive Agreement” of Form 8-K.
On March 12, 2026, CytomX Therapeutics, Inc. (the “Company”) received written notice from Astellas Pharma Inc. (“Astellas”) of Astellas’s termination of the Collaboration and License Agreement, dated as of March 23, 2020, by and between Astellas and the Company (the “Agreement”). Astellas exercised its right to terminate the Agreement, with such termination effective as of May 12, 2026.
The foregoing summary of the termination does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which was filed as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 7, 2020. For a summary of the material terms of the Agreement, please see Note 8, Collaboration and License Agreements to our audited financial statements included elsewhere in this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.